Reporters and editors from the Pink Sheet, MedTech Insight and HBW Insight discuss the first 100 days of US Food and Drug Administration Commissioner Robert Califf’s goals, accomplishments, trials and tribulations, across the drug, device and health and wellness sectors and whether ongoing and how crises like the infant formula shortage could affect them. They also consider the potential for lasting change at the agency going forward.
Podcast Special: Assessing US FDA Commissioner Robert Califf’s First 100 Days
Reporters and editors from the Medtech Insight and sister publications covering the pharmaceutical and health, beauty and wellness sectors look at Califf’s goals, accomplishments and trials during the early days of his second term.
More from Regulation
• By
The US FDA needs to know who wants a seat at the MDUFA negotiations table before discussions can begin. The agency is asking stakeholders to let it know if they plan to participate in the periodic consultation meetings before July 28.
• By
Finland has initiated a project to improve the effectiveness of the monitoring of software intended for medical use and to ensure that software placed on its market meets the requirements set for it.
• By
To succeed in medtech, investors must focus on patient outcomes. Gilde Healthcare says involving patients boosts product effectiveness, access and market success — making it a smart strategy in today’s strained healthcare systems.
• By
MedTech Europe is ready to become involved and shape Europe’s Life Sciences Strategy and help drive regulatory simplification from the top to make the EU “the world’s most attractive place for life sciences by 2030.”